EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Ianalumab plus Eltrombopag in Immune Thrombocytopenia

Adam Cuker, Thomas Stauch, Nichola Cooper, Hanny Al-Samkari iD, Marc Michel, Waleed Ghanima, Patrick Urban, Justyna Fronczek, Matthew Foster, Marine Weill, Lei Zhang, Ming Hou und 15 weitere

New England Journal of Medicine · 16.04.2026 · 394 (15) · 1503-1513

DOI: 10.1056/nejmoa2515168 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.04.2026. Verfasst von Adam Cuker und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Benzoates, Hydrazines, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBenzoatesHydrazinesPurpura, Thrombocytopenic, IdiopathicPyrazolesAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Therapy, CombinationKaplan-Meier EstimatePlatelet CountReceptors, ThrombopoietinTreatment FailureB-Cell Activation Factor ReceptorB-LymphocytesYoung AdultAged, 80 and over

Substanzen

Antibodies, Monoclonal, HumanizedBenzoateseltrombopagHydrazinesPyrazolesReceptors, ThrombopoietinianalumabB-Cell Activation Factor Receptor

Autor:innen und Institutionen

  • Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Department of Internal Medicine II, Hematology and Oncology, University Hospital Jena, Jena, Germany.
  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College, London.
  • Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
  • Østfold Hospital Trust, Kalnes, Norway.

ORCID-Profile: Hanny Al-Samkari

Förderung

  • Novartis

Zitieren

APA

Cuker, A., Stauch, T., Cooper, N., Al-Samkari, H., Michel, M., Ghanima, W., Urban, P., Fronczek, J., Foster, M., Weill, M., Zhang, L., Hou, M., Zander, T., Sharif, A., Sun, J., Nath, U. K., Schutgens, R., Rossi, E., Deleu, L., …, & VAYHIT2 Investigators (2026). Ianalumab plus Eltrombopag in Immune Thrombocytopenia. New England Journal of Medicine, 394(15), 1503-1513. https://doi.org/10.1056/nejmoa2515168

Vancouver

Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, et al. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. New England Journal of Medicine. 2026;394(15):1503-1513. doi:10.1056/nejmoa2515168

BibTeX
@article{Cuker2026,
  author = {Cuker, Adam and Stauch, Thomas and Cooper, Nichola and Al-Samkari, Hanny and Michel, Marc and Ghanima, Waleed and Urban, Patrick and Fronczek, Justyna and Foster, Matthew and Weill, Marine and Zhang, Lei and Hou, Ming and Zander, Thomas and Sharif, Azizan and Sun, Jing and Nath, Uttam Kumar and Schutgens, Roger and Rossi, Elena and Deleu, Lien and Červinek, Libor and Yoon, Jae-Ho and Chang, Hung and Ruchutrakool, Theera and Iino, Masaki and Goto, Tatsunori and Zaja, Francesco and VAYHIT2 Investigators, VAYHIT2 Investigators},
  title = {Ianalumab plus Eltrombopag in Immune Thrombocytopenia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {15},
  pages = {1503--1513},
  doi = {10.1056/nejmoa2515168}
}
Kostenlos starten →